Kornimate/medical-research-clean huggingface dataset:
alterations in protein synthesis rates of burn patients measured over time using pet scans

Conditions: Burn

Summary: our specific aim is to gain an understanding of protein synthesis rates in burn patients at various times during their injury and recovery by using pet scans. this will be compared with healthy volunteer controls. we hope this will help optimize nutrition and care regimens for future burn patients.

the purpose of this study is to understand how muscles are built up and broken down (metabolism) in both burn patients and healthy people.the studies will help us understand how muscle metabolism is different for burn patients and healthy subjects. we hope to find ways to help the body of a burn victim heal without losing too much muscle. protein is an important part of our daily diet. normally, the body breaks down the protein we eat into smaller pieces called amino acids. it uses the amino acids to make its own proteins. it uses these proteins to heal wounds, fight infections, and provide energy. after a burn injury, the body speeds up the pace of its life activities. it needs more energy just to stay alive and recover from the burn. the body often gets the extra energy it needs by breaking the protein in muscles down into amino acids. the amino acids are then made into new proteins. if too much muscle is broken down, it is harder for the body to function. this can make recovery slower or possibly lead to death. for healthy volunteers, this study will require no more than 6 hours of time in total. this time will be spread out over two visits, a screening visit and a scan visit. for burn patients, this study will require no more than 14 hours total. this time will be spread out over four visits-a screening visit and a maximum of 3 scan visits. a total of three pet scans will be done over a 2 year period.

Eligibility criteria:
inclusion criteria: for healthy volunteers healthy males and females 18-70 years of age. laboratory results within mgh-accepted normal range. within 20% of the ideal weight for their height. supine and standing blood pressure within the range of 110/60 to 150/90 mm hg heart rate within the range of 46-90 beats/minute after 5 minutes of rest. subjects \ =24, age 40-60 with hct \>=27, age 60-70 with hct \>=30. for burn subjects: inclusion criteria: burn injury of \>=5 % tbsa from any cause. 18 -70 years of age stable hemodynamic and cardiopulmonary states as judged by the attending surgeons in the burn unit. patient who is capable of giving full informed consent. exclusion criteria: for healthy subjects clinical evidence of physical or mental disease. clinically significant abnormality of the laboratory tests. known drug or alcohol dependence. history of drug allergy taking standard prescription drugs within two weeks or investigational drugs within four weeks prior to the pet scan diabetes mellitus and other metabolic endocrine disorders pregnant or lactating for burn subjects: pregnant or lactating females

Keywords: protein synthesis rate burn injury pet scan
treating hepatitis c in crf using sofosbuvir and daclatasvir

Conditions: Hepatitis C, Chronic; Chronic Renal Failure

Summary: sofosbuvir is the base of most treatment regimens for hepatitis c. in patients with renal failure the blood level of one of its metabolites (gs-331007) rises up to 20 folds. although no particular adverse event has been linked to this metabolite sofosbuvir is not recommended for patients with renal failure mainly because of lack of data. nevertheless there are anecdotal reports and small studies proving the safety of sofosbuvir in renal failure. this study addresses this lack of information by evaluating the safety and efficacy of sofosbuvir and daclatasvir in treating hepatitis c in 100 patients with renal failure.


Eligibility criteria:
inclusion criteria: * positive qualitative hepatitis c virus rna test on two occasions at least 6 months apart * renal failure (egfr \< 30 cc/min) or under hemodialysis exclusion criteria: * model for end-stage liver disease (meld) score \> 20, * child's c (ctp score \> 12), * heart rate \< 50/min, * taking amiodarone

Keywords: hepatitis c renal failure sofosbuvir daclatasvir
study of apatinib in advanced hepatocellular carcinoma(hcc)

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced hcc.

hepatocellular carcinoma (hcc) is the most common primary malignant tumor of the liver. it is lack of effective drugs for systemic treatment of hcc. currently, sorafenib is the only choice approved by fda for advanced hcc, although it prolongs the survival for less than 3 months. the treatment of advanced hcc still has a long way to go. at present, the relevant phase ii and phase iii clinical studies of apatinib on advanced hcc are ongoing. based on our important discovery of our previous clinical studies, we intends to enlarge the sample size and make further observation for the efficacy and safety of apatinib in patients with advanced hcc.

Eligibility criteria:
inclusion criteria: 1. before doing any research steps, the patient's informed consent must be obtained first. 2. the diagnosis of hcc: histologic diagnosis or alpha fetoprotein (afp) with two kinds of imaging diagnosis. 3. patients of barcelona stage(bclc) c with first-line treatment failure or non tolerance to sorafenib. 4. ages of 18 to 75 years old. 5. child-pugh score between 5-7 points, patients of child-pugh 7 points should be without ascites. 6. eastern cooperative oncology group performance score (ecog ps) is 0-1 point. 7. adequate organ function meeting the following: hemoglobin(hbg)≧9.0g/dl neutrophil count(anc) ≧1,500/mm3 platelet count(plt)≧50,000/ul total bilirubin (tbil)\ 50% or pt-inr\<2.3, \<6 seconds or greater than that of the control 8. for patients taking warfarin, at least once a week to a close monitoring of the patients, until, according to the standard of treatment, at every time of medication, the subjects' inr measurements has been stable 9. scr (serum creatinine) \<1.5×uln 10. for pregnant women, the results of serum pregnancy tests must be negative within 14 days before initiation of treatment. 11. all men and women who participated in the study had to take reliable contraceptive measures within the trial and two weeks of after the trial. exclusion criteria: 1. patients of child-pugh 7 has serious uncontrolled ascites. 2. patients with serious cardiovascular disease. 3. patients with high blood pressure of unable to control. 4. patients has the history of hiv (human immunodeficiency virus) infection. 5. active clinical severe infection (\> 2, nci-ctcae version 3). 6. need to drug treatment of patients with epilepsy (such as steroid or antiepileptic drugs) 7. has a history of allogeneic organ transplantation. 8. patients with a history of physical signs or have a bleeding. 9. patients undergoing renal dialysis. 10. metastatic liver cancer. 11. patients with uncontrollable ascites. 12. patients with encephalopathy. 13. patients has history of gastrointestinal bleeding period of 30 days before join the study. 14. patients with a history of esophagus varicosity burst hemorrhage, then not effective treatment or therapy to prevent recurrence of bleeding.

Keywords: apatinib advanced hepatocellular carcinoma
novel medications for opiate detoxification - 4

Conditions: Opioid-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to evaluate novel medications for opiate detoxification.


Eligibility criteria:
please contact site for information.

Keywords: opioid-related disorders
integrated neuromuscular inhibition versus cervical and scapular stabilization exercises on myofascial trigger points of upper trapezius

Conditions: Trigger Point Pain, Myofascial

Summary: this trial will involve three groups. the integrated neuromuscular inhibition group will receive the integrated neuromuscular inhibition technique. the cervical and scapular stabilization group will receive cervical and scapular stabilization exercises. the ultrasound group will receive ultrasound therapy


Eligibility criteria:
inclusion criteria: * patients with active trigger points in the upper trapezius for more than 2 weeks based on the simons criteria. * age ranged from 18-25 years. * pain intensity ≥ 3 on vas. * females and males. exclusion criteria: * patients indicated for surgery. * patients with symptomatic disc lesions. * patients with rheumatological diseases or traumatic neck injury. * patients injected with corticosteroids in the last 6 months.
study to evaluate the safety and pharmacokinetics of ckd-349 in healthy adult volunteers

Conditions: Chronic Heart Failure

Summary: study to evaluate the safety and pharmacokinetics of ckd-349

an open label, randomized, single-dose, 2-sequence, 2-period, cross-over phase 1 study to evaluate the safety and pharmacokinetics of ckd-349 in healthy adult volunteers

Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged ≥ 19 years 2. weight ≥50kg (man) or 45kg (woman), with calculated body mass index (bmi) of 18 to 30 kg/m2 3. those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings. 4. those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ecg results at screening. 5. those who agree to contraception until 7 days after clinical trial. 6. individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial. exclusion criteria: 1. those who have clinically significant diseases or history in digestive systems, cardiovascular system, endocrine system, respiratory system, blood·tumor, infectious disease, kidney and urogenital system, mental·nervous system, musculoskeletal system, immune system, otolaryngology, skin system, ophthalmology system, etc. 2. those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery. 3. those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month before the first administration of investigational products or take drugs that may interfere with this clinical trials within 10 day before the first administration 4. those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs. 5. those who donated whole blood within 8 weeks or donated ingredients within 2 weeks, or received a blood transfusion within 4 weeks. 6. those who exceed an alcohol and cigarette consumption than below criteria a. alcohol: man- 21 glasses/week, woman - 14 glasses/week (1 glass: soju 50ml, wine 30ml, or beer 250ml) b. smoking: 20 cigarettes/day 7. those who overreacts to the ingredient of this drug and is administering an angiotensin conversion enzyme (ace) inhibitor or has not passed 36 hours since discontinuation of administration and has a history of vascular edema when administering an angiotensin conversion enzyme (ace) inhibitor or an angiotensin receptor antagonist (arb). 8. those who are deemed insufficient to participate in this clinical study by investigators. 9. woman who are pregnant or breastfeeding.
bilateral gluteal fascio-myo-cutaneous flap in treatment of recurrent pilonidal disease

Conditions: Pilonidal Sinus

Summary: bilateral gluteal fascio-myo-cutaneous advancement flap is a modified technique used in treatment of recurrent sacrococcygeal pilonidal sinus

patients with recurrent pilonidal sinus disease are recruited to undergo bilateral gluteal fascio-myo-cutaneous advancement flap technique under spinal anesthesia in order to prevent recurrence.

Eligibility criteria:
inclusion criteria: * patients with recurrent sacrococcygeal pilonidal disease aging more than 16 years with single or multiple pits were included in the study. * patients included presented with recurrence of pilonidal disease at least six months after the first operation. exclusion criteria: * patients aging less than 16 years. * patients unfit for anesthesia. * patients with primary pilonidal disease. * patients with acute pilonidal abscess or active infection.
epione® post-market clinical follow-up study

Conditions: Cancer Abdomen

Summary: post-market clinical follow-up study in order to consolidate performance and safety data of the epione® device when used for percutaneous procedures in the abdomen

the objective of this pmcf study is to compile data on the routine use of the epione® device in subjects undergoing ct-guided percutaneous procedures in the abdomen. the objectives are: 1. to evaluate the technical success of the device 2. to evaluate performance parameters (accuracy measures, adjustements, post-intervention ablation success, local tumor recurrence, operator satisfaction) and the safety of the device 55 patients are planned in this post-market study.

Eligibility criteria:
inclusion criteria: * patient \>18 years old, * patient for whom a ct-guided procedure in abdomen has been prescribed and agreed by a multidisciplinary team of radiologists, surgeons and clinicians, * patient with a confirmed non-opposition. exclusion criteria: * patient unable to undergo general anesthesia, * pregnant or breast-feeding females

Keywords: percutaneous ct-guided ablation biopsy abscess drainage fiducial placement abdomen liver kidney robotics
epidemiology study in postmenopausal women with estrogen receptor positive breast cancer

Conditions: Hormon Receptor Positive Breast Cancer

Summary: this observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (ai) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.


Eligibility criteria:
inclusion criteria: * postmenopausal females with estrogen receptor positive breast cancer that are currently treated with aromatase inhibitor (ai) medication * provision of subject informed consent exclusion criteria: * if participating in any clinical trial, the subject cannot take part in this study.

Keywords: compliance hr+ breast cancer epidemiology
dynamic surface exercise and trunk targeted training in children with spastic cerebral palsy

Conditions: Spastic Cerebral Palsy

Summary: this study aims to describe the comparative effects of dynamic surface training and trunk targeted training in order to ensure which method is best in improving gross motor function , balance and trunk control in children with spastic cerebral palsy . this will be randomized control study which includes participants with age 5 to 10 years

cerebral palsy (cp) is a well-documented nonprogressive neurodevelopmental condition commencing in early childhood and persisting throughout life. the neuromuscular deficits observed in children with cp include abnormal muscle tone that affects posture, movement, alteration of balance and motor coordination, decrease in strength, and loss of selective motor control, leading to functional limitation. neurodevelopmental principles state that the control of movement proceeds from the proximal to the distal part of the body. the trunk being the central key point of the body, proximal trunk control is a prerequisite for distal limb movement control, balance, and functional mobility. using dynamic surface for exercise provides proprioceptive and vestibular feedback about the position of their body segments in space with adaptive motor control response to stimuli. standard physiotherapy based on motor-learning principle is task-specific training, which involves practice of functional movements in activities of daily living. this study aims to describe the comparative effects of dynamic surface training and trunk targeted training in order to ensure which method is best in improving gross motor function , balance and trunk control in children with spastic cerebral palsy . this will be randomized control study which includes participants with age 5 to 10 years. data will be taken from shahida islam teaching hospital lodhran after taking consent, techniques will be applied and data will be recorded. assessment will be made by using pedriatics balance scale , gross motor function measure (gmfm 66) and trunk control measurement scale (tcms) for determining balance and gross motor function and trunk stability . the collective data will be analyzed in statistical package for social sciences (spss) 27.0

Eligibility criteria:
inclusion criteria: children who can follow the therapist instructions * children who have not had any procedure and surgery within the past six months * both genders male and female * age 5 to 10 years * spastic cerebral palsy exclusion criteria: * children with innate musculoskeletal diseases, developing central nervous system diseases and history of orthopedic surgery * children with genetic disorders and other severe diseases other than cerebral palsy * children who had botulinum toxin a (bont-a) injection during the last 6 months or had seizures during the last one year were excluded from the study * children with visual impairement * children with hearing impairemen

Keywords: balance cerebral palsy dynamic surface training gross motor function.
breastmilk alone or in combination with paracetamol for reducing pain

Conditions: Pain Control

Summary: efficacy of expressed breast milk alone or in combination with paracetamol in reducing pain during rop screening.

retinopathy of prematurity (rop) has been widely acknowledged to be the primary cause of preventable childhood blindness in developing countries. however, the procedure for screening is extremely painful. in this study, we will attempt to relieve the pain experienced by these babies using breast milk alone or in combination with oral paracetamol. this randomized control trial study will be conducted with the aim to assess the efficacy of expressed breast milk alone or in combination with paracetamol in reducing pain during rop screening. all preterm neonate who undergone rop screening will be the study population. a total of 60 preterm neonates will be randomized into three groups: (group a - control group = 20, group b - breast milk group = 20, and group c - oral paracetamol + breast milk = 20). group a will get current care as per institutional protocol, group b received 2 ml expressed breast milk (ebm) through a sterile syringe orally 2 min prior to procedure, group c received syrup paracetamol, 15 mg/kg 30 min prior to procedure and ebm as in group b. pain experienced was measured by the premature infant pain profile (pipp) score 20 s prior, during and 2 min after procedure. all procedures were video recorded. the ophthalmologist and analyzer both will be blinded to the intervention. results will be incorporated after enrollment

Eligibility criteria:
inclusion criteria: * 1. gestational age \<35 weeks, and birth weight \<2000 gm exclusion criteria: * 1. parents of neonate who refused to participate in the study 2. newborns with multiple congenital anomalies 3. patient who is on mechanical ventilator during rop examination 4. neonate receiving narcotic or sedative drugs 5. neonate not receiving oral feed.
1st line treatment of bevacizumab-taxane vs bevacizumab-exemestane in metastatic breast cancer

Conditions: First Line Metastatic Breast Cancer

Summary: in first-line metastatic breast cancer, the bevacizumab-taxane to progression or toxicity, is currently the standard treatment. in patients expressing hormone receptors, it was shown that hormone therapy administered in maintenance after induction chemotherapy, could have a benefit regarding the progression-free survival. the investigators make the hypothesis that there would be interest to discontinue treatment with taxane after 4 months, and to begin hormone therapy while continuing maintenance bevacizumab. exemestane was chosen because it has been shown potentially active in patients who progressed after letrozole, anastrozole or tamoxifen.


Eligibility criteria:
inclusion criteria: * age \> 18 ans. * metastatic breast cancer or locally advanced * re+, her2- * patient receiving paclitaxel-bevacizumab first line chemotherapy exclusion criteria: * previous treatment by exemestane (both in adjuvant or metastatic treatment). * 1st line of chemotherapy different thaan paclitaxel-bevacizumab. * treatment by paclitaxel-bevacizumab \> 18 weeks. * her2 positifs et/ou récepteurs aux oestrogènes négatifs. * previous thrombosis event within the 6 months before inclusion . * previous significant surgery within the 28 days before treatment start * previuous coagulopathy.

Keywords: first line metastatic breast cancer positive estrogen receptors negative her2 receptors at least stable disease after 4 months of paclitaxel-bevcizumab induction chemotheray
post-stroke medication relay

Conditions: Stroke, Ischemic; Medication Compliance

Summary: prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects). improvements in the use of medications in the community and in hospital follow-up. telephone interviews or teleconsultations will make it possible to assess the patient's knowledge of his or her treatment and to re-explain it if necessary to improve patient compliance with treatment.


Eligibility criteria:
inclusion criteria: * adult patients managed in stroke unit following ischemic stroke * benefiting from a direct return home * non-opposition to participation exclusion criteria: - none
sars-cov-2 (covid-19) immune surveillance among a population based sample of adults in florida

Conditions: Coronavirus Infection

Summary: the overall goal of this study is to understand the immune response (igg) to sars-cov-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. the study team aims to assess the prevalence of circulating igg antibodies to sars-cov-2 and the factors associated with sero-prevalence. these data will be used to estimate the total population that has been exposed to the virus (asymptomatic and symptomatic), the proportion of the population that may be protected by natural immunity, and the proportion that is susceptible. data obtained from this research will be shared with the florida department of health.


Eligibility criteria:
inclusion criteria: * resident of hillsborough county, florida * 18 years of age or older * currently not exhibiting symptoms of sars-cov-2 infection

Keywords: covid -19 sarc-cov-2